(NASDAQ: PRCT) Procept Biorobotics's forecast annual revenue growth rate of 17.92% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 6.13%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.09%.
Procept Biorobotics's revenue in 2026 is $352,304,000.On average, 16 Wall Street analysts forecast PRCT's revenue for 2026 to be $23,205,468,322, with the lowest PRCT revenue forecast at $21,651,993,055, and the highest PRCT revenue forecast at $24,309,586,484. On average, 16 Wall Street analysts forecast PRCT's revenue for 2027 to be $27,985,569,254, with the lowest PRCT revenue forecast at $25,486,200,158, and the highest PRCT revenue forecast at $29,484,960,568.
In 2028, PRCT is forecast to generate $33,373,251,625 in revenue, with the lowest revenue forecast at $30,786,427,625 and the highest revenue forecast at $35,281,149,397.